Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase - Wikidata - wikimedia - TriplyDB

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase

http://www.wikidata.org/entity/Q28067422

about

Novel treatment options for the management of heterozygous familial hypercholesterolemia.

P2860

Q47836175-96CEEE15-8BDA-4536-BB5A-FE3254C0F55B

P2860

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase

http://www.wikidata.org/entity/Q28067422

description

2016 nî lūn-bûn

@nan

2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase

@ast

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase

@en

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase

@nl

type

label

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase

@ast

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase

@en

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase

@nl

prefLabel

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase

@ast

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase

@en

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase

@nl

P1433

Q28067422-849E6297-336A-4EEA-86FF-3A4109F3DBC0

P1476

Q28067422-AFACE857-2CD3-4280-B13B-233EF9364FCB

P2093

Q28067422-AC66CCA7-8921-477D-B913-C8C45857A008

Q28067422-B534A263-E01B-401F-84E0-FD0F5B3AF9AF

P275

Q28067422-06B104D2-56BD-42F2-B0F7-AF2C17D7A204

P2860

Q28067422-03D11B35-78B0-4784-BD29-779B26CF5835

Q28067422-0AA0A155-E753-460E-AE3B-ED3E7E9D028E

Q28067422-319167CA-A39E-4C90-AB56-FF7240C304BA

Q28067422-50707256-5F8E-4811-BB61-911337CEE545

Q28067422-56F68069-BC64-4F2F-930A-3160BBF76136

Q28067422-6100CAC8-83F0-46BC-A36C-DAF68D73DC29

Q28067422-69465714-5CA0-4BA0-8751-A3073FB93B44

Q28067422-74A63195-4746-4970-B912-009E084DF048

Q28067422-82A09A76-7901-4CB9-85B9-59F84977C861

Q28067422-84C687D7-7AAE-4A44-A507-4EF97C099BAF

P2888

Q28067422-FE77D7B7-104F-4082-83A0-14DBD6CD49C4

P304

Q28067422-FDE7D5F9-0465-4512-BFD6-6C0843E1243E

P31

Q28067422-B332895A-8A11-48DC-8E26-5ACE0996CB80

Q28067422-E3529B88-85C6-4CEB-9482-C9D73905C5AD

P3181

Q28067422-B1D2B90A-4096-461E-8B0F-924B72AA7283

P356

Q28067422-172B5708-DC4F-40EF-BB3C-158EDB8D7803

P407

Q28067422-EAEA2C33-6CCF-4206-9916-0C10FE21B170

P433

Q28067422-67BACA53-EA25-4F77-830E-2B3E788FF8C5

P478

Q28067422-D7B4BDC6-8726-44A7-BFE5-4004DF788C4F

P577

Q28067422-8D914CEB-8509-42FD-ADC0-64980D7955C2

Q28067422-BE51E727-D384-4FE6-A9BB-EBEED03F3AF8

P6179

Q28067422-7D95A497-CA49-46A7-9FDF-49EA7E8763B1

P698

Q28067422-51D6C159-1401-421A-92C5-C4ACC3846651

P921

Q28067422-4B83685B-6E2A-4A2B-A2B4-C0569893C850

Q28067422-961C4449-BE99-40E1-A7A5-1F5228689714

Q28067422-BB7D66FE-64D3-4767-9677-37BF8E7CC310

Q28067422-D6339258-2A48-4355-AE4C-6993A63B77A1

Q28067422-ED15EAF1-B5CD-4C70-8A86-45594CC98132

P932

Q28067422-0CC5CA71-215F-4DCB-860D-B21FF81E6AB8

P3181

P356

S11883-016-0611-4

P1433

Current Atherosclerosis Reports

P1476

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase

@en

P2093

Christie M. Ballantyne

http://www.w3.org/2001/XMLSchema#string

Ozlem Bilen

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia.

Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden.

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Deficiency in hepatic ATP-citrate lyase affects VLDL-triglyceride mobilization and liver fatty acid composition in mice

Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative.

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Contemporary management and attainment of cholesterol targets for patients with dyslipidemia in China.

AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism.

The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis.

ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK

P2888

s11883-016-0611-4

P304

61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3227621

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S11883-016-0611-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1002610647

http://www.w3.org/2001/XMLSchema#string

P698

27663902

http://www.w3.org/2001/XMLSchema#string

P921

carboxylic acid

mechanism of action

P932

5035316

http://www.w3.org/2001/XMLSchema#string